Zalutumumab in Non-curable Patients With SCCHN

August 2, 2023 updated by: Genmab

An Open Label Single Arm Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination With Best Supportive Care, in Patients With Non-Curable Squamous Cell Carcinoma of the Head and Neck Who Have Failed Standard Platinum-based Chemotherapy.

Treatment, In combination with BSC, Open-label, Single arm, Efficacy Study.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
90

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Austria
      • Graz, Austria, 8036
        • MEDIZINISCHE UNIVERSITAT GRAZ
      • Salzburg, Austria, 5020
        • Universitätsklinik für Innere Medizin III
      • Wien, Austria, 1090
        • AKH Wien
  • Chile
      • Temuco, Chile
        • Instituto Clinico Oncologico del Sur ICOS
      • Valparaiso, Chile
        • Hospital Carlos Van Buren de Valparaiso
      • Viña del Mar, Chile
        • Instituto Oncologico
  • Colombia
      • Bogota, Colombia
        • Centro de Investigaciones Oncologicas Clinica CIO San Diego S.A
      • Medellin, Colombia
        • Hospital Pablo Tobon Uribe
      • Montería, Colombia
        • Oncomedica S.A.
      • Pereira, Colombia
        • Oncólogos del Occidente S.A.
  • Czechia
      • Hradec Králové, Czechia, 500 05
        • Facultni Nemocnice Hradec Kralove
      • Jihlava, Czechia, 586 33
        • Nemocnice Jihlava
      • Prague, Czechia, 128 08
        • Veseobecna Fakultni Nemocnice
      • Prague, Czechia, 180 81
        • Facultni Nemocnice Na Bulovce
  • Germany
      • Essen, Germany, 45122
        • Universitatsklinikum Essen
      • Frankfurt am Main, Germany, 60590
        • Klinikum Der Johann Wolfgang Goethe Universitat
      • Freiburg, Germany, 79106
        • Uniklinik Freiburg
      • Heidelberg, Germany, 69120
        • Universitatsklinikum Heidelberg
      • Lübeck, Germany, 23538
        • Medizinische Universitätsklinik Lübeck
      • Nordhausen, Germany, 99734
        • Südharz-Krankenhaus Nordhausen gGmbH
  • Israel
      • Beer Sheva, Israel, 84101
        • Soroka Medical Center
      • Haifa, Israel, 31096
        • Rambam Medial Center
      • Jerusalem, Israel, 91031
        • Shaare-Zedek Medical Center
      • Petah Tikva, Israel, 49100
        • Rabin Medical Center
      • Ramat-Gan, Israel, 52621
        • Sheba Medical Center
      • Tel-Aviv, Israel, 64239
        • Sourasky Medical Center
  • Italy
      • Milan, Italy, 20133
        • Istituto Nazionale Tumori
      • Milan, Italy, 20141
        • Istituto Europea di Oncologia
      • Sondrio, Italy, 23100
        • Azienda Ospedaliera Valtellina e Valchiavenna
  • Peru
      • Arequipa, Peru
        • Hospital Goyeneche
      • Arequipa, Peru
        • Hospital Nacional Carlos Alberto Seguin Escobedo
      • Lambayeque, Peru
        • Hospital Nacional Almanzor Aguinaga Asenjo
      • Lima, Peru
        • Hospital Central FAP
      • Lima, Peru
        • Hospital Nacional Guillermo Almenara Irigoyen
  • Portugal
      • Coimbra, Portugal, 3000-075
        • Ipo Coimbra
      • Lisboa, Portugal, 1099-023
        • Ipo Lisboa
      • Porto, Portugal, 4200-072
        • Ipo Porto
  • Slovakia
      • Bratislava, Slovakia, 83310
        • Narodny onkologicky ustav
      • Trnava, Slovakia, 917 75
        • FN Trnava
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35294-0012
        • University of Alabama at Birmingham
    • California
      • Loma Linda, California, United States, 92354
        • Loma Linda University Cancer Institute
    • Florida
      • Tampa, Florida, United States, 33612
        • Moffitt Cancer Center
    • Idaho
      • Boise, Idaho, United States, 83712
        • Mountain States Tumor Institute
    • Illinois
      • Chicago, Illinois, United States, 60637
        • University of Chicago Medical Center
    • Indiana
      • Fort Wayne, Indiana, United States, 46815
        • Ft. Wayne Medical Oncology/Hematology, Inc
    • Michigan
      • Detroit, Michigan, United States, 48202
        • Henry Ford Health Systems
    • Oregon
      • Portland, Oregon, United States, 97239
        • Oregon Health and Science University
    • Texas
      • Dallas, Texas, United States, 75246
        • Baylor University Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Males and females age ≥ 18 years
  2. Confirmed diagnosis, initially or at relapse, of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, considered incurable with standard therapy
  3. Failure to at least one course of standard platinum-based chemotherapy

Exclusion Criteria:

  1. Three or more prior chemotherapy regimens
  2. Prior treatment with EGFr antibodies and/or EGFr small molecule inhibitors
  3. Past or current malignancy other than SCCHN, except for certain other cancer diseases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Zalutumumab 4-16 mg/kg
Zalutumumab iv infusion once weekly. The dose was titrated until grade 2 rash occurred.
Drug: Zalutumumab
Individual dose titration weekly i.v. doses

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Overall Survival (OS)
Time Frame: From randomization until death, assessed up to 21 months
OS was defined as time from start of treatment until date of death of any cause.
From randomization until death, assessed up to 21 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Objective Tumour Response
Time Frame: During treatment and two weeks after end of treatment, assessed up to 21 months.
Objective Tumour response according to Response Evaluation Criteria in Solid Tumours (RECIST v 1.0). Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the longest diameter of target lesions; Overall Response (OR), CR+PR. Stable disease is Responses not fulfilling CR, PR or progressive disease (PD). PD is At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started, OR the appearance of one or more new lesions.
During treatment and two weeks after end of treatment, assessed up to 21 months.
Duration of Response
Time Frame: During treatment and two weeks after end of treatment, assessed up to 21 months
DOR is defined among responders, as the time from the initial documentation of response to the date of disease progression or death, whichever occurs earlier.
During treatment and two weeks after end of treatment, assessed up to 21 months
Progression Free Survival (PFS)
Time Frame: During treatment and two weeks after end of treatment, assessed up to 21 months
PFS is defined as the time from start of treatment until disease progression or death.
During treatment and two weeks after end of treatment, assessed up to 21 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Genmab

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Steen Lisby, MD, Genmab A/S, Bredgade 34, DK-1260 Copenhagen K, Denmark

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2008

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 1, 2011

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 1, 2011

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 10, 2007

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 10, 2007

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 11, 2007

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 3, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 2, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • GEN205

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings